Synthetic lethality: Triple combination is a viable strategy for B-cell malignanciesDecember 11, 2020B Cell LymphomaDLBCLCLL
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemiaNovember 24, 2020CLLB Cell Lymphoma
Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patientsNovember 10, 2020CLL
Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapiesOctober 7, 2020CLL
Two new protein biomarkers may serve as prognostic indicators for outcomes in CLLSeptember 23, 2020CLL
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020DLBCLFollicular LymphomaCLLMantle Cell LymphomaB Cell Lymphoma
BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patientsAugust 11, 2020CLL
